Product Reports Resources Pricing Login Book a demo

23andMe

Biotech & Life Sciences · Sunnyvale, United States · Founded 2006 · Public via SPAC 2021

Helping people access, understand, and benefit from the human genome

Valuation $150M
Revenue $190M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

18 investors on 23andMe's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Genentech
Mohr Davidow Ventures
Stephens Investment Management
Alphabet | Google
NEA
Series B+ 13 investors entered at this stage
Johnson & Johnson Development Corporation
GSK
Fidelity Investments
Sequoia
NewView Capital
Illumina
Sergey Brin
Casdin Capital
Yuri Milner
Xfund
Anne Wojcicki
MPM BioImpact
Future Planet Capital

23andMe mafia

Startups founded by 23andMe alumni

Former 23andMe employees who went on to start their own companies. Sorted by Dealroom signal score.

BioptimusEst. 2023
Eric DurandFrance
Signal score93
LevelsEst. 2019
Casey MeansUnited States
Signal score90
Brightside HealthEst. 2017
Brad KittredgeUnited States
Signal score85
Agua BlancaEst. 2021
Pierre-Eric LeiboviciFrance
Signal score84
MainStreetEst. 2019
JTJesse TinsleyUnited States
Signal score81
Hexagon BioEst. 2016
BNBrian NaughtonUnited States
Signal score80
10X GenomicsEst. 2012
Serge SaxonovUnited States
Signal score80
ColingoEst. 2011
Angel StegerUnited States
Signal score77
Xili TechnologyEst. 2021
PYPeng YueUnited States
Signal score75
Rosemary HealthEst. 2019
Romain BonjeanAustralia
Signal score74
Kanaph TherapeuticsEst. 2019
Byoung-Chul LeeSouth Korea
Signal score74
TractEst. 2020
EWEsther WojcickiUnited States
Signal score73

Book a demo to explore the full alumni network →

Global footprint

Where 23andMe has talent and traffic

Workforce by country
13 countries with
team presence
🇺🇸 United States95.3%
🇨🇳 China0.8%
🇧🇩 Bangladesh0.4%
🇧🇷 Brazil0.4%
🇦🇷 Argentina0.4%
Top 5 of 13 shown
Web traffic by country
4.2M monthly visits
across markets
🇺🇸 United States74.2%
🇨🇦 Canada5.5%
🇬🇧 United Kingdom5.1%
🇹🇭 Thailand1.2%
🇦🇪 United Arab Emirates1.1%
Top 5 markets shown

Talent graph

The shape of 23andMe's talent

Dealroom maps 23andMe's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 standout operatorsDealroom-flagged across the org
14 AI specialistsincl. 4 core researchers
548 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock 23andMe's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$54M patent portfolio · 50 active families

Estimated portfolio value
$54M
36.0% of market cap · 6.4× smaller than top peer Ginkgo Bioworks ($349M)
50 active patent families
Where 23andMe innovates Bio informaticsBioinformaticsComputational biologyData bankData masking

Where 23andMe concentrates vs peers

Each axis is a top-10 topic across 23andMe and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

23andMe's 4 investments and acquisitions.

Every disclosed deal where 23andMe appeared as a backer or acquirer, 2012–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across 23andMe's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where 23andMe deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        23andMe's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about 23andMe

        An AI-synthesized read of the highest-engagement posts about 23andMe on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See 23andMe on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles